Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 1, 1997, Pages 274-278

  Morse, Jane H ^a   Barst, Robyn J ^b   Fotino, Marilena ^b   Zhang, Yun ^b   Flaster, Edith ^b   Gharavi, Azzudin E ^b   Fritzler, Marvin J ^b   Dominguez, Miguel ^b   Angles Cano, Eduardo ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; EPITOPE; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNITY; BLOOD VESSEL INJURY; CHILD; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031018254     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.1.9001324     Document Type: Article

References (35)

1. Rubin, L. J. 1993. Primary pulmonary hypertension. Chest 104:236-250.
2. Winslow, T. M., M. A. Ossipov, G. P. Fazio, J. S. Simonson, R. F. Redberg, and N. B. Schiller. 1995. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am. Heart J. 129:510-515.
3. Stupi, A. M., V. D. Steen, G. R. Owens, E. L. Barnes, G. P. Rodnan, and T. A. Medsger, Jr. 1986. Primary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 29:515-524.
4. Barst, R. J., E. R. Flaster, A. Menon, M. Fotino, and J. H. Morse. 1992. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex. Circulation 85:249-258.
5. Theopoulos, A. N. 1995. The basis of autoimmunity: Part II Genetic predisposition. Immunology Today 16:150-159.
6. Rich, S., K. Kieras, B. M. Groves, J. D. Stobo, and B. H. Brundage. 1986. Antinuclear antibodies in primary pulmonary hypertension. J. Am. Coll. Cardiol. 8:1307-1311.
7. Isern, R. A., M. Yaneva, E. Wiener, A. Parke, N. Rothfield, D. Dantzker, and S. Rich. 1992. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am. J. Med. 93: 307-312.
8. Yaneva, M., and R. C. Arnett. 1989. Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin. Exp. Immunol. 76:366-372.
9. Angles-Cano, E., P. Grailhe, C. Boyer-Neumann, F. Brenot, E. Peynaud-Debayle, R. Azarian, G. Simonneau, P. Duroux, and D. Meyer. 1994. Markers of endothelial involvement in chronic pulmonary hypertension (abstract). Fibrinolysis 8(Suppl. 1):139.
10. Boyer-Neumann, C., F. Brenot, M. Wolf, E. Peynaud-Debayle, P. Duroux, D. Meyer, E. Angles-Cano, and G. Simonneau. 1995. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thrombosis and Haemostasis 73:735-736.
11. Ruiz-Arguelles, A., E. Angles-Cano, B. Perez-Romano, G. J. Ruis-Arguelles, M. Deleze, D. Alarcon-Segovia, and P. Gaussem. 1995. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am. J. Hematol. 49:109-114.
12. Salazar-Paramo, M., I. Garcia de la Torre, M. J. Fritzler, S. Loyau, and E. Angles-Cano. 1996. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus (SLE) are associated with Raynaud's phenomenon and thrombosis. Lupus 5:275-278.
13. Fritzler, M. J., D. A. Hart, D. Wilson, I. Garcia-De La Torre, M. Salazar-Paramo, M. Vasquez-Del Mercado, J.-L. Senecal, and E. Angles-Cano. 1995. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J. Rheumatol. 22:1688-1693.
14. Morse, J. H., Y. Zhang, M. Fotino, and R. J. Barst. 1994. Primary pulmonary hypertension (PPH) is associated with HLA-DQ7 (DQBI* 0301) in Caucasians. Circulation 90(4):1-149.
15. Morse, J. H., R. J. Barst, S. Itescu, E. R. Flaster, G. Sinha, Y. Zhang, and M. Fotino. 1996. Primary pulmonary hypertension in HIV-infection: An outcome determined by particular HLA class II alleles. Am. J. Respir. Crit. Care Med. 153:1299-1301.
16. D'Alonzo, G. E., R. J. Barst, S. M. Ayers, E. H. Bergofsky, B. H. Brundage, K. M. Detre, A. P. Fishman, R. M. Goldring, B. M. Groves, J. T. Kernis, P. S. Levy, G. G. Pietra, L. M. Reid, J. T. Reeves, S. Rich, C. E. Vriem, G. W. Williams, and M. Wu. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Int. Med. 115:343-349.
17. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271-1277.
18. Subcommittee for Scleroderma Criteria of the American Rheumatism Diagnostic and Therapeutic Criteria Committee. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:581-590.
19. 2 glycoprotein I on binding to phospholipid. J. Rheumatol. 21:94-99.
20. Angles-Cano, E. 1986. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high fibrinaffinity tissue plasminogen activators. Ann. Biochem. 153:201-210.
21. Olerup, O., and H. Zetterquist. 1992. HLA DR typing by amplification with sequence specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donorrecipient matching in cadaveric transplantation. Tissue Antigens 39:225-235.
22. SAS Institute, Inc. 1988. SAS Procedures Guide. SAS Institute, Inc., Cary, NC.
23. McNeil, H. P., R. J. Simpson, C. N. Chesterman, and S. A. Krilis. 1990. Antiphospholipid antibodies are directed against a complex antigen glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. U.S.A. 87:4120-4124.
24. 2-glycoprotein I. J. Clin. Invest. 90:1100-1104.
25. Giad, A., M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy, H. Shennib, S. Kimura, T. Masaki, W. P. Duguid, and D. J. Stewart. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-1739.
26. Christman, B. W., C. D. McPherson, J. H. Newman, G. A. King, G R. Bernard, B. M. Groves, and J. E. Lloyd. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327:70-75.
27. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. J. Engl. J. Med. 333:214-221.
28. Eisenberg, P. R., C. Lucore, L. Kaufman, B. E. Sobel, A. S. Jaffe, and S. Rich. 1990. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82:841-847.
29. Fuster, V., P. M. Steele, W. D. Edwards, M. D. McGoon, and R. L. Frye. 1984. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70:580-587.
30. Rich, S., F. Kaufmann, and P. S. Levy. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327:76-81.
31. Barst, R. J., L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. H. Tapson, R. C. Bourge, B. H. Brundage, S. K. Koerner, D. Langleben, C. A. Keller, S. Murali, B. F. Uretsky, L. M. Clayton, M. M. Jobsis, S. D. Blackburn, D. Shortino, and J. W. Crow. 1996. A comparison of continuous intravenous epoprostenol with conventional therapy in primary pulmonary hypertension. N. Engl. J. Med. 334:296-301.
32. Pepke-Zaba, J., T. W. Higenbottam, A. T. Dinh-Xuan, D. Stone, and J. Wallwork. 1991. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 338:1173-1174.
33. Angles-Cano, E., Y. Sultan, and J.-P. Clauvel. 1979. Predisposing factor to thrombosis in systemic lupus erythematosus. Possible relation to endothelial damage. J. Lab. Clin. Med. 94:312-323.
34. Arnett, F. C., M. L. Olsen, K. L. Anderson, and J. D. Reveille. 1991. Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J. Clin. Invest. 87:1490-1495.
35. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three dimensional structure ot human-class II histocompatibility HLA-DR1. Nature 364: 33-39.